Theravance Biopharma Company Profile (NASDAQ:TBPH)

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Theravance Biopharma, Inc. (NASDAQ:TBPH) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($1.27) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.14) by $0.13. The company earned $3.09 million during the quarter, compared to analyst estimates of $5.07 million. Theravance Biopharma had a negative net margin of 641.67% and a negative return on equity of 67.69%. View Theravance Biopharma's Earnings History.

Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Theravance Biopharma.

8 analysts have issued 1-year target prices for Theravance Biopharma's shares. Their forecasts range from $24.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $42.00 in the next year. View Analyst Ratings for Theravance Biopharma.

Here are some recent quotes from research analysts about Theravance Biopharma stock:

• 1. Needham & Company LLC analysts commented, "Theravance mgmt hosted a 4Q16 conference call late yesterday to provide a corporate update. We note several expected milestones in 2017. Results from Phase 1b TD-1473 trial in Ulcerative Colitis in mid-2017 are of particular interest, given size of market and differentiated mechanism (GI-restricted JAK inhibitor). We are favorably inclined. A second distinct JAK inhibitor, TD-3504 (GIrestricted tofacitinib prodrug), is expected to enter Phase 1 testing in 1H17 as a backup option. Other events include NDA submission for revefenacin in Chronic Obstructive Pulmonary Disease w/ collaborator Mylan, potential FDA approval of Closed Triple by collaborator GSK, as well as results from Phase 2 trials of TD-9855 in Neurogenic Orthostatic Hypotension and velusetrag in Gastroparesis." (2/28/2017)
• 2. According to Zacks Investment Research, "Theravance’s sole marketed product, Vibativ, continues to perform well, contributing meaningfully to the top line at the company. However, Vibativ witnessed a sequential decline due to seasonality and trends in surgical admissions. Nevertheless, the company’s efforts on the commercialization of Vibativ are encouraging. We are also positive on its efforts to expand the drug’s label, which if approved for additional indications, would be commercially significant. Further, its collaboration agreement with Mylan for revefenacin, a key late-stage pipeline candidate, is a big positive. Theravance’s progress with the rest of the pipeline is also impressive. Shares of the company have significantly outperformed the Medical-Drugs industry in 2016. Moreover, estimates have gone up ahead of the release of the company’s fourth-quarter 2016 results. However, Theravance’s heavy dependence on Vibativ for growth is concerning." (1/3/2017)
• 3. Leerink Swann analysts commented, "We reiterate our Outperform rating for Theravance’s stock. Stronger than expected Vibativ sales driven by a combination of new indication and expansion of dedicated sales force. Sales of Vibativ increased by 62% QoQ and 152% YoY apparently driven by the expansion of the sales force from 6 to 50 reps in 4Q15 and the opportunity presented by the expanded label. Mgmt believes the growth in revenue will continue driven by the expansion of accounts and positive physician perception in using Vibativ in difficult to treat patients. Several catalysts in next 12 months could potentially add additional value to the company. As highlighted in our earlier note [LINK], our sum of the parts analysis identified potential 20% and 70% upside by end of 2016 and 2017, respectively." (8/9/2016)

Some companies that are related to Theravance Biopharma include Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Horizon Pharma PLC (HZNP), Cambrex Corporation (CBM), Amicus Therapeutics (FOLD), Pacira Pharmaceuticals (PCRX), Innoviva (INVA), Impax Laboratories (IPXL), Corcept Therapeutics Incorporated (CORT), Amphastar Pharmaceuticals (AMPH), Lannett Co (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Aceto Corporation (ACET), Teligent (TLGT), Collegium Pharmaceutical (COLL) and Aquinox Pharmaceuticals (AQXP).

Theravance Biopharma's management team includes the folowing people:

• Rick E. Winningham, Chairman of the Board, Chief Executive Officer
• Renee D. Gala, Senior Vice President, Chief Financial Officer, Treasurer
• Bradford J. Shafer Esq. J.D., Executive Vice President, General Counsel, Secretary
• Brett K. Haumann M.D., Senior Vice President - Clinical Development and Chief Medical Officer
• Sharathchandra S. Hegde, Senior Vice President, Research
• Frank Pasqualone, Senior Vice President and Chief Commercial Operations Officer
• Kenneth R. Pitzer, Senior Vice President - Product Strategy and Commercial Planning
• Philip D. Worboys Ph.D., Senior Vice President, Translational Science
• William D. Young, Lead Independent Director
• Eran Broshy, Independent Director

Theravance Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.04%), Public Employees Retirement Association of Colorado (0.02%) and Aperio Group LLC (0.01%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Burton G Malkiel, Junning Lee, Plc Glaxosmithkline, Renee D Gala and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma.

Theravance Biopharma's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Aperio Group LLC. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Junning Lee, Plc Glaxosmithkline, Renee D Gala and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.

Shares of Theravance Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Theravance Biopharma stock can currently be purchased for approximately $33.48.